Neutrophil-activating therapy for the treatment of cancer

• Published in: Cancer cell Vol. 41; no. 2; pp. 356 - 372.e10
• Main Authors: Linde, Ian L., Prestwood, Tyler R., Qiu, Jingtao, Pilarowski, Genay, Linde, Miles H., Zhang, Xiangyue, Shen, Lei, Reticker-Flynn, Nathan E., Chiu, David Kung-Chun, Sheu, Lauren Y., Van Deursen, Simon, Tolentino, Lorna L., Song, Wen-Chao, Engleman, Edgar G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13.02.2023
• Subjects: Animals; Antineoplastic Agents; C5a; cancer immunotherapy; CD40; complement; Humans; leukotriene B4; Leukotriene B4 - metabolism; Leukotriene B4 - pharmacology; Mice; Neoplasms - drug therapy; Neoplasms - metabolism; neutrophil; Neutrophils; reactive oxygen species; tumor immunology; tumor necrosis factor; Tumor Necrosis Factor-alpha - metabolism; xanthine oxidase; CD40; tumor immunology; tumor necrosis factor; cancer immunotherapy; reactive oxygen species; complement; neutrophil; xanthine oxidase; C5a; leukotriene B4

Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents. Here, we demonstrate in mouse models that neutrophils can be...